GoodRx (Foundayo + Zepbound KwikPen) vs MyStart Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
MyStart Health
Best for fastest compounded GLP-1 onboarding with a price lockStarting at $299/mo
Side-by-Side Comparison
| Feature | GoodRx (Foundayo + Zepbound KwikPen) | MyStart Health |
|---|---|---|
| Overall Score | ✓8.4/10 | 7.7/10 |
| Starting Price | ✓$149/mo | $299/mo |
| Editorial Rating | ✓4.2 ★ /5 | 3.9 ★ /5 |
| Features | 6 features | 6 features |
| States Available | ✓50 | 0 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
MyStart Health
Pros
- ✓Price Lock Guarantee — base monthly rate ($299) doesn't increase even when your prescribed dose escalates
- ✓Fast onboarding: quoted 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- ✓24/7 access to the care team with unlimited clinician messaging included
- ✓LegitScript certified
- ✓Transparent Section 503A compounding disclosure on every landing page
Cons
- ✗Not BBB accredited — BBB rating of C+ with 10 complaints filed against the business (BBB file opened April 24, 2025), most involving shipping delays and customer service access issues in early 2026
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Oral tirzepatide referenced in marketing but FAQ clarifies injectable is 'currently more common' — no FDA-approved oral tirzepatide exists, and the November 2025 Chimicles class action against OpenLoop/Triad Rx over unapproved oral tirzepatide products is a cautionary data point for the category
- ✗Very recent company (incorporated May 21, 2024 per BBB) — limited operational track record
- ✗Pharmacy partners not publicly named — no independent way to verify 503A compliance
- ✗Clinical efficacy claims are based on a homepage survey of only 16 self-reporting customers
Our Verdict
GoodRx (Foundayo + Zepbound KwikPen) edges out MyStart Health with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. MyStart Health remains a solid alternative, especially if you're looking for fastest compounded GLP-1 onboarding with a price lock.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.